阿尼鲁单抗改善难治性多系统皮肌炎:病例系列
本文回顾了2024年4月至8月在约翰斯·霍普金斯医院皮肤科接受每4周300 mg阿尼鲁单抗输注的4例成人起病难治性皮肌炎患者,所有患者皮肤病变均改善,中位CDASI-A下降12分或49.4%;患者1-3的关节、吞咽、肌力和肌酸激酶等皮肤外表现亦改善,未观察到阿尼鲁单抗相关不良事件。
要点
- 4例难治性成人皮肌炎患者接受阿尼鲁单抗300 mg每4周输注后皮肤病变均改善。
- 中位CDASI-A下降12分或49.4%(范围5-21;26.9-77.8%)。
- 患者1-3皮肤外症状改善,患者1和4减少或停用全身治疗包括激素。
核心结论
- 本病例系列首次显示阿尼鲁单抗有潜力治疗成人起病难治性皮肌炎的皮肤外表现、促进泼尼松减量并停用全身治疗。
- 这些发现提供新证据表明系统性阻断I型干扰素可管理难治性多器官皮肌炎表现,包括皮肤、关节和肌肉受累。
研究设计与样本
- 回顾性病例系列,纳入约翰斯·霍普金斯医院皮肤科皮肤自身免疫性结缔组织病门诊管理的成人起病皮肌炎患者。
- 患者于2024年4月至8月间因难治性疾病接受阿尼鲁单抗300 mg每4周输注。
- 共识别4例患者,收集人口学、疾病严重度、实验室检查、皮肤病生活质量指数(DLQI)和治疗详情。
- 皮肤改善采用皮肌炎皮肤疾病面积和严重度指数-活动度(CDASI-A)评估,皮肤外症状通过实验室结果、体格检查和主观报告评估。
主要发现
- 患者1和3在3次输注后、患者2和4在2次输注后评估临床应答。
- 所有患者皮肤病变均改善,中位(范围)CDASI-A下降12分或49.4%(5-21;26.9-77.8%)。
- 患者1-3皮肤外症状亦改善,包括关节痛/滑膜炎、吞咽困难、肌力和肌酸激酶水平。
- 患者1和4减少或停用包括激素在内的全身治疗。
- 两名患者有阿尼鲁单抗治疗前DLQI数据,治疗后显示改善;未观察到阿尼鲁单抗相关不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate anifrolumab's ability to treat cutaneous and extracutaneous manifestations of dermatomyositis (DM) refractory to conventional systemic therapies. METHODS: We reviewed the records of patients with adult-onset DM managed at the Cutaneous Autoimmune Connective Tissue Disease Clinic in the Department of Dermatology at Johns Hopkins Hospital who received 300 mg infusions of anifrolumab every 4 weeks between April and August 2024 for refractory disease. Data on demographics, disease severity, lab findings, Dermatology Life Quality Index (DLQI) and treatment details were collected. Cutaneous improvement was evaluated using the Cutaneous Dermatomyositis Disease Area and Severity Index-Activity (CDASI-A), while extracutaneous symptoms were assessed through lab results, physical exams and subjective reports. RESULTS: Four patients were identified. Clinical responses were assessed after three infusions for patients 1 and 3 and two infusions for patients 2 and 4. All patients showed improvement in cutaneous disease, with a median (range) CDASI-A reduction of 12 points or 49.4% (5-21; 26.9-77.8%). Patients 1-3 also experienced improvement in extracutaneous symptoms, including arthralgia/synovitis, dysphagia, muscle strength and creatine kinase levels. Patients 1 and 4 tapered or discontinued systemic therapies including steroid. Pre-anifrolumab DLQI data, available for two patients, showed post-treatment improvement. No anifrolumab-related adverse effects were observed. CONCLUSIONS: This case series is the first to demonstrate anifrolumab's potential to treat refractory extracutaneous manifestations of adult-onset DM, facilitate prednisone tapering and discontinue systemic therapies. These findings provide new evidence that systemic blockade of type I interferon can manage treatment-resistant multi-organ DM manifestations, including skin, joint and muscle involvement.
引用
- Patel S, Jeurling S, Albayda J, et al. Improvement of recalcitrant multisystem disease in dermatomyositis with anifrolumab: a case series. Rheumatology (Oxford). 2025. PMID: 40663397. doi:10.1093/rheumatology/keaf388
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。